Background: Anti-TNF therapy is well established in the treatment of moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). Therapeutic effect may wane over time leading to secondary loss of response that can be overcome with dose escalation. Data on rate of secondary loss of response is extremely limited. Aims: We sought to determine real-world rates of secondary loss of response to anti-TNF therapy in CD and UC and to identify patient and disease factors predictive of loss of response. Methods: All 23 prescribers of anti-TNF medications for IBD in Manitoba agreed to participate in the study. Charts of biologic-naive patients started on anti-TNF therapy between 2005 and 2016 were reviewed and demographics, disease characteristics, and IBD treatments recorded. Secondary loss of response was defined by the use of augmented dose anti-TNF therapy after a minimum of 90 days on standard dose anti-TNF. Survival curves were constructed and statistical analysis conducted using Student's t-test, chi squared test, and log rank test. Results: 670 patients started anti-TNF therapy during the period in question (483 CD, 182 UC, and 5 IBD-U). 233 CD subjects (48.2%) had penetrating disease while 92 UC subjects (50.5%) had pancolitis. Mean age at diagnosis was 29.4 years and 50.0% of subjects were female. Secondary non-responders did not differ from the overall anti-TNF cohort in disease phenotype or demographics. No differences in IBD-related surgeries, hospitalizations, or inflammatory markers prior to initiating anti-TNF therapy were observed. Mean duration of follow up was 32.5 months. Secondary loss of response occurred in 9% of subjects by 6 months, 25% by 12 months, and 39% by 24 months. Thereafter response was durable, with only an additional 4% drop off over five years of treatment. There was a trend toward lower loss of response among infliximab users, but this did not reach the level of significance (p=0.07). Time to loss of response was significantly greater among anti-TNF subjects receiving concomitant immunomodulators (p=0.006). The beneficial effect of combination therapy was limited to infliximab subjects (p=0.0002) with no benefit observed among adalimumab users (p=0.80). Secondary loss of response rate did not differ between CD and UC (p=0.51).
Conclusions:
Over 40% of IBD subjects treated with anti-TNF therapies ultimately lose response and require dose augmentation, with the majority of cases occurring within the first 24 months. Loss of response is significantly less common among infliximab users receiving concomitant immunomodulators.
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